Insider Selling: Martine Rothblatt Sells 3,833 Shares of United Therapeutics Corp. Stock (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine Rothblatt sold 3,833 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $76.98, for a total value of $295,064.34. Following the transaction, the chief executive officer now directly owns 140 shares in the company. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of United Therapeutics Corp. (NASDAQ:UTHR) in a research note to investors on Thursday. They now have a $81.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $75.00 to $85.00 in a research note to investors on Monday, August 5th. They now have a “buy” rating on the stock. Finally, analysts at Guggenheim raised their price target on shares of United Therapeutics Corp. (NASDAQ:UTHR) from $61.00 to $69.00 in a research note to investors on Tuesday, July 30th. They now have a “neutral” rating on the stock.
Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $63.60.
Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.26% during mid-day trading on Thursday, hitting $77.15. 318,534 shares of the company’s stock traded hands. United Therapeutics Corp. has a 52-week low of $44.51 and a 52-week high of $78.38. The stock’s 50-day moving average is $73.26 and its 200-day moving average is $66.51. The company has a market cap of $3.852 billion and a P/E ratio of 13.34.
United Therapeutics Corp. (NASDAQ:UTHR) last announced its earnings results on Thursday, July 25th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.05. The company had revenue of $280.60 million for the quarter, compared to the consensus estimate of $250.17 million. During the same quarter in the previous year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 24.4% on a year-over-year basis. Analysts expect that United Therapeutics Corp. will post $5.99 EPS for the current fiscal year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.